Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
ARX517 Anti-PSMA ADC for Prostate and Other Cancers
ARX517 Shows Encouraging Single-Agent Safety and Efficacy Data in ...
Trial of ARX517 Doses First Patient With a PSMA-Expressing Solid Tumor
ARX517 Demonstrates Early Efficacy With Favorable Safety in Heavily ...
ARX517 Antibody Drug Conjugate Begins Trials in Prostate Cancer ...
ARX517 demonstrates continued safety and efficacy in mCRPC
FDA Grants Fast Track Designation for ARX517 in Metastatic Castration ...
ARX517 Shows Promising Safety and Efficacy in mCRPC | Targeted Oncology ...
FDA grants Fast Track Designation to ARX517 for metastatic castration ...
Dr Pachynski on the Ongoing Investigation of ARX517 in Advanced Solid ...
ESMO 2023: APEX-01: First-in-Human Phase 1/2 Study of ARX517, an Anti ...
Preclinical Characterization of ARX517, a Site-Specific Stable PSMA ...
首款靶向PSMA ADC临床结果超预期，Ambrx借此缓解阵痛，信心大增！ 欢迎关注 凯莱英 药闻2023年2月16日，Ambrx宣布其正在 ...
Slide 11
Ambrx Reports Advances in APEX-01, Phase 1/2 Trial of ARX517, a PSMA ...
Ambrx旗下PSMA ADC获FDA授予快速通道资格 7月19日，Ambrx宣布ARX517获FDA授予快速通道资格，用于治疗接受雄激素受体 ...
Ambrx股价涨54%：公布PSMA ADC一期临床数据 Armstrong 2023年2月16日， Ambrx Biopharma 公布 ...
Ambrx 技术平台及ADC管线梳理 - 知乎
速递 | 靶向前列腺特异性膜抗原（PSMA），ADC药物完成1期试验首例给药_临床
Ambrx Announces ARX517, a PSMA-Targeted ADC, Demonstrates a
Anti-PSMA ADC：临床前药代动力学（PK）实验流程深度解析
靶向PSMA的ADC药物ARX517获美国FDA快速通道资格-上市-医保-临床适应症-香港济民药业
盘点 | 诺华PSMA靶向疗法获批，拜耳、安进等都在开发，PSMA的开发前景有多大？_治疗_细胞_患者
Examples of PSMA expression on immunohistochemistry (IHC)... | Download ...
1828P ARX517: A next generation anti-PSMA antibody drug conjugate (ADC ...
Abstract CT121: ARX517, an anti-PSMA ADC targeting mCRPC resistant or ...
Ambrx Announces ARX517, a PSMA-Targeted ADC, Demonstrates a Promising ...
首款靶向PSMA ADC临床结果超预期，Ambrx借此缓解阵痛，信心大增！_腾讯新闻
Novel Treatment Targets in the Metastatic Castrate-Resistant Prostate ...
Preclinical and Clinical Status of PSMA-Targeted Alpha Therapy for ...
前列腺癌标志物：PSMA|前列腺癌|PSMA|标志物|ADC|疗法|细胞|肿瘤|药物|-健康界
靶向PSMA单域抗体ADC药物的药效研究|PSMA|靶向|药效|抗体|肿瘤|-健康界
Slide 12
Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of ...
ARX-517(ARX-517) - 药物靶点：PSMA x Tubulin_在研适应症：前列腺腺癌，转移性去势抵抗性前列腺癌，前列腺癌_专利 ...
PSMA：前列腺癌明星靶点 - 知乎
Emerging Data Behind 2 Antibody Drug Conjugates for Breast and Prostate ...
Prostate-Specific Membrane Antigen-Targeted Antibody–Drug Conjugates: A ...
AMAM | ARX517, Ambrx’s Proprietary Anti-PSMA ADC, Shows Encouraging ...
前列腺癌强效ADC新药来袭：ARX517获FDA快速通道认定资格-出国看病-盛诺一家
速递｜潜在“first-in-class”治疗晚期癌症，PSMA靶向ADC临床试验结果积极_腾讯新闻
Anti-PSMA Antibody (ARX517 antibody) | 抗PSMA抗体 | MCE
Full article: Emerging conjugation strategies and protein engineering ...
PPT - Target And Clinical Trial Progress of ADC In prostate Cancer ...
UCSF Prostate Cancer Trial → ARX517/JNJ-95298177 as Monotherapy or ...
ASCO五分钟丨朱耀教授：“最优化”PSMA放射性配体疗法-肿瘤瞭望
开发针对 PSMA 的新型 111In/225Ac 标记药物，用于高效癌症放射治疗,Journal of Medicinal ...
Chemical structures of the prostate-specific membrane antigen (PSMA ...
Imaging of Tumor-Associated Vascular Prostate-Specific Membrane Antigen ...
下一代新型ADC: 点击化学ADC - 知乎
强生约20亿美元收购Ambrx，囊获多款临床期ADC - 四川省医药保化品质量管理协会
Prostate-specific membrane antigen (PSMA) targeted singlet oxygen ...
PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant ...
Phase I trial of ARX517, an anti-PSMA ADC, in mCRPC - YouTube
A Single-Domain Antibody-Based Anti-PSMA Recombinant Immunotoxin ...
A Supramolecular Self-Assembling Nanoagent by Inducing Intracellular ...
Novel Prostate specific membrane antigen (PSMA)-targeted drug ...
177Lu-Labeled Albumin-Binder–Conjugated PSMA-Targeting Agents with ...
Updated Guidelines Focus on Advanced Prostate Cancer
Frontiers | Advancements in PSMA ligand radiolabeling for diagnosis and ...
Prostate-specific Membrane Antigen PET in Prostate Cancer | Radiology
Chemical structures of selected prostate-specific membrane antigen ...
[ARX517] - Side effects - Acute kidne... - Advanced Prostate...
Ambrx: Next-Generation Antibody-Drug Conjugates, Buying The Dip After ...
ARX517-hIgG1 - Kyinno Bio
Why Ambrx Biopharma Shares Are Surging Today?
乳腺癌抗HER2靶向治疗药物,抗体偶联(ADC)药物ARX788疾病控制率100%,ARX788治疗HER2阳性的乳腺癌临床试验招募正在进行中 ...
PSMA-Targeting Imaging and Theranostic Agents—Current Status and Future ...
Advances in targeted alpha therapy for prostate cancer - Annals of Oncology
Size Matters: Arginine-Derived Peptides Targeting the PSMA Receptor Can ...
.png)
